In September, China increased its gold reserves by 21 tonnes, marking the biggest monthly gain in three years and continuing a 23-month streak of purchases. This move came as gold prices fell, with the People's Bank of China now holding 2,196 tonnes of gold. China's foreign exchange reserves slightly declined due to currency and asset price changes but remain stable overall. The sustained gold buying reflects central banks' strategy to accumulate gold amid economic and geopolitical uncertainties, with China and Poland leading global purchases in 2026.
China's central bank gold purchases reached 21 tonnes in September, the largest monthly increase in three years. For readers following US stocks on Pluang, here is the market snapshot as of Oct 07, 2026 20:31 WIB: out of 150 priced stocks, 41 rose and 107 fell. Notable movers include Macy's Inc (M) at USD 21.58 with a 1-day change of -3.92%, Barclays PLC (BCS) at USD 22.81 with a 1-day change of -3.63% and 100% buy order activity, and Gold Fields Limited (GFI) at USD 34.93 with a 1-day change of -3.43% and 89% sell order activity.
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
Barclays has lowered its price target for Netflix shares from $80 to $70 due to concerns over slower revenue growth and rising content costs, especially for live programming. Despite Netflix's large subscriber base of 325 million, the company faces p...
Jefferies analyst Andrew Tsai lowered Rocket Pharmaceuticals' price target to $2.95, with shares trading at $2.48. The company is advancing its gene therapy for Danon disease, RP-A501, with an FDA-aligned pivotal study plan. Rocket secured $35 millio...
Eight Wall Street firms raised their price targets for Zscaler following the company's $10 billion Annual Recurring Revenue (ARR) goal announcement, with targets now implying a 29% upside from current prices. While most analysts maintain Buy or Overw...
